폐암 치료 시장 : 치료 유형별, 투여 경로별, 치료 단계별, 병기별, 처방 상황별, 유통 채널별, 암 유형별, 최종사용자별 - 세계 예측(2026-2032년)

The Lung Cancer Therapeutics Market is projected to grow by USD 59.89 billion at a CAGR of 8.77% by 2032.

Lung cancer therapeutics are being reshaped by precision oncology, immuno-oncology, antibody-drug conjugates, radioligand and bispecific approaches, and earlier molecular testing across non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). According to global cancer surveillance data, lung cancer remains one of the most frequently diagnosed cancers worldwide and the leading cause of cancer mortality, reinforcing the urgency for therapies that improve survival while reducing toxicity.

The market is increasingly defined by biomarker-directed treatment for EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, HER2, and KRAS G12C alterations, alongside PD-1, PD-L1, and CTLA-4 immune checkpoint inhibitors. As treatment algorithms move from late-stage disease into adjuvant, neoadjuvant, and perioperative settings, commercial opportunity is expanding beyond drug launch performance to include companion diagnostics, real-world evidence, access strategy, adherence support, and sequencing intelligence.

Transformative Shifts in the Lung Cancer Therapeutics Landscape

The lung cancer treatment landscape has shifted from broad chemotherapy regimens toward personalized, biomarker-led care. Comprehensive genomic profiling is now central to NSCLC management, while liquid biopsy is improving testing access when tissue is limited or repeat biopsy is impractical. These changes are accelerating earlier identification of actionable mutations and enabling more precise therapy selection across metastatic and earlier-stage disease.

Transformative shifts also include immunotherapy combinations, next-generation tyrosine kinase inhibitors, bispecific antibodies, and antibody-drug conjugates designed to address resistance, improve intracranial activity, and extend durable response. In SCLC, where progress has historically been slower, chemo-immunotherapy, DLL3-directed approaches, PARP pathway research, and novel maintenance strategies are creating renewed clinical and commercial momentum.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across lung cancer therapeutics, improving discovery, trial design, diagnostics, and treatment monitoring. AI-enabled imaging tools support earlier nodule detection and risk stratification, while computational biology helps identify drug targets, resistance mechanisms, and patient subgroups most likely to respond to targeted therapy, immunotherapy, or combination regimens.

In clinical development, AI is improving site selection, eligibility matching, protocol feasibility, synthetic control design, pharmacovigilance, and real-world evidence generation. For commercial and medical affairs teams, machine learning can help map testing gaps, therapy sequencing, adherence risks, referral leakage, and regional access barriers. The strongest near-term value will come from governed AI systems integrated with validated clinical data, pathology workflows, imaging repositories, privacy safeguards, and regulatory-grade evidence standards.

Key Regional Insights Across Major Lung Cancer Therapeutics Markets

North America remains a leading region for lung cancer therapeutics due to high biomarker testing adoption, advanced oncology infrastructure, rapid uptake of approved targeted therapies and immunotherapies, and strong participation in clinical trials. Europe continues to expand precision oncology through national cancer plans, health technology assessment frameworks, screening programs, and cross-border research networks, although reimbursement timelines and molecular testing access can vary across countries.

Asia-Pacific is one of the most strategically important regions because of its high disease burden, large patient populations, and elevated prevalence of EGFR-mutated NSCLC in several East Asian populations. Latin America is improving access to immunotherapy and molecular diagnostics, but affordability, referral pathways, and testing infrastructure remain uneven between public and private systems. The Middle East is investing in oncology centers, genomic medicine, and specialist cancer care, particularly in GCC markets, while Africa faces the greatest access challenges, including late diagnosis, limited pathology and radiotherapy capacity, fragmented cancer registries, and constrained reimbursement for innovative lung cancer drugs.

Key Group Insights for Lung Cancer Therapeutics Strategy

The G7 continues to influence global lung cancer therapeutics through innovation funding, regulatory leadership, premium oncology reimbursement, and extensive clinical trial networks. The European Union is central to harmonized regulatory pathways, cancer screening initiatives, joint evidence generation, and cross-country oncology policy alignment, while NATO countries collectively represent a large base of advanced oncology infrastructure, academic research centers, and pharmaceutical demand.

BRICS markets are increasingly important because China, India, Brazil, Russia, and South Africa combine large patient pools, expanding domestic pharmaceutical capabilities, and rising use of targeted therapy where diagnostics and reimbursement are available. ASEAN countries are improving oncology capacity, but access differs substantially between Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines due to variation in insurance coverage, pathology capacity, and specialist availability. GCC markets are prioritizing specialty care investment, genomic testing, public-sector modernization, and medical tourism, creating opportunities for premium lung cancer therapeutics when clinical evidence, reimbursement, and local partnerships align.

Key Country Insights in Lung Cancer Therapeutics

The United States is a highly influential market for lung cancer therapeutics, supported by regulatory innovation pathways, broad clinical trial activity, guideline-driven biomarker testing, and strong adoption of targeted therapy and immunotherapy. Canada follows evidence-based reimbursement processes and pan-Canadian oncology assessment practices, while Mexico and Brazil are expanding oncology access amid budget constraints and variability between public and private systems. The United Kingdom, Germany, France, Italy, and Spain remain critical European markets shaped by national HTA decisions, cancer care pathways, screening priorities, and molecular testing programs, while Russia faces access variability linked to health system funding, regional disparities, and geopolitical pressures.

China is a major growth engine due to high lung cancer incidence, domestic innovation, faster regulatory review for priority therapies, and rapid expansion of targeted therapy and immunotherapy. Japan and South Korea are mature precision oncology markets with strong diagnostics capability, active clinical research, and high relevance for EGFR-directed treatment. India offers significant long-term potential due to a large patient base and rising oncology investment, but requires affordability-focused strategies, broader molecular testing access, and cancer infrastructure expansion. Australia benefits from advanced cancer care, public reimbursement mechanisms, organized clinical trial networks, and active participation in global lung cancer research.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker access as a growth enabler, not only a clinical requirement. Partnerships with pathology networks, liquid biopsy providers, hospitals, oncology societies, and payers can reduce missed testing opportunities and support appropriate use of targeted therapies and immunotherapies across NSCLC and selected SCLC settings.

Organizations should also build evidence strategies that demonstrate survival benefit, quality-of-life impact, sequencing value, safety management, and budget relevance. Successful commercialization will require differentiated positioning in crowded PD-1/PD-L1 and TKI segments, investment in resistance-management pipelines, trial designs that reflect biomarker-defined populations, equitable access models in emerging markets, and compliant AI tools that improve trial execution and real-world decision support.

Research Methodology

This executive summary is based on secondary research and analytical synthesis of publicly available, evidence-based sources, including global cancer epidemiology data, regulatory approvals, clinical practice guidelines, peer-reviewed oncology literature, clinical trial registries, health technology assessment trends, reimbursement policy updates, and cancer control publications.

The methodology emphasizes triangulation across disease burden, treatment standards, biomarker prevalence, regulatory activity, reimbursement environment, diagnostic infrastructure, and regional access conditions. Insights were evaluated for relevance to lung cancer therapeutics, including NSCLC, SCLC, targeted therapies, immunotherapies, antibody-drug conjugates, companion diagnostics, liquid biopsy, resistance mechanisms, real-world evidence, and AI-enabled oncology applications.

Conclusion

Lung cancer therapeutics are entering a more precise, data-intensive, and competitive era. The strongest market participants will be those that connect innovative medicines with diagnostic readiness, payer-relevant evidence, AI-enabled operational efficiency, and practical access strategies across developed and emerging healthcare systems.

As treatment moves earlier in the disease course and resistance mechanisms become central to pipeline planning, durable advantage will depend on integrated oncology ecosystems. Organizations that combine scientific differentiation with regional execution discipline, equitable testing access, and evidence-based sequencing strategies are best positioned to improve outcomes and capture growth in the global lung cancer therapeutics market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Lung Cancer Therapeutics Market, by Therapy Type

• 7.1. Chemotherapy
  • 7.1.1. Alkylating Agents
  • 7.1.2. Platinum-Based
  • 7.1.3. Taxanes
  • 7.1.4. Topoisomerase Inhibitors
• 7.2. Immunotherapy
  • 7.2.1. CTLA-4 Inhibitors
  • 7.2.2. PD-1 Inhibitors
  • 7.2.3. PD-L1 Inhibitors
• 7.3. Radiation Therapy
  • 7.3.1. Brachytherapy
  • 7.3.2. External Beam Radiation
  • 7.3.3. Stereotactic Body Radiation
• 7.4. Supportive Care
  • 7.4.1. Antiemetics
  • 7.4.2. Bone-Modifying Agents
  • 7.4.3. Hematopoietic Growth Factors
• 7.5. Surgery
• 7.6. Targeted Therapy
  • 7.6.1. Anaplastic Lymphoma Kinase (ALK) Inhibitors
  • 7.6.2. BRAF Inhibitors
  • 7.6.3. EGFR Inhibitors

8. Lung Cancer Therapeutics Market, by Mode Of Administration

• 8.1. Inhalation
• 8.2. Injectable
• 8.3. Oral

9. Lung Cancer Therapeutics Market, by Line Of Therapy

• 9.1. First-Line
• 9.2. Second-Line
• 9.3. Third-Line & Beyond

10. Lung Cancer Therapeutics Market, by Disease Stage

• 10.1. Stage I
• 10.2. Stage II
• 10.3. Stage III
• 10.4. Stage IV

11. Lung Cancer Therapeutics Market, by Prescription Status

• 11.1. Branded
• 11.2. Generic

12. Lung Cancer Therapeutics Market, by Distribution Channel

• 12.1. Offline Retail
• 12.2. Online Retail

13. Lung Cancer Therapeutics Market, by Cancer Type

• 13.1. Non-Small Cell Lung Cancer (NSCLC)
  • 13.1.1. Adenocarcinoma
  • 13.1.2. Large Cell Carcinoma
  • 13.1.3. Squamous Cell Carcinoma
• 13.2. Small Cell Lung Cancer (SCLC)

14. Lung Cancer Therapeutics Market, by End User

• 14.1. Ambulatory Infusion Centers
• 14.2. Cancer Centers
• 14.3. Homecare Settings
• 14.4. Hospitals

15. Lung Cancer Therapeutics Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Lung Cancer Therapeutics Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Lung Cancer Therapeutics Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. AstraZeneca PLC
• 19.2. Merck & Co., Inc.
• 19.3. F. Hoffmann-La Roche Ltd
• 19.4. Bristol-Myers Squibb Company
• 19.5. Regeneron Pharmaceuticals Inc.
• 19.6. Novartis AG
• 19.7. Daiichi Sankyo, Inc.
• 19.8. Pfizer Inc.
• 19.9. Eli Lilly and Company
• 19.10. Johnson & Johnson Services, Inc.
• 19.11. Amgen Inc.
• 19.12. Takeda Pharmaceutical Company Limited
• 19.13. GlaxoSmithKline plc
• 19.14. AbbVie Inc.
• 19.15. Astellas Pharma Inc.
• 19.16. Bayer AG
• 19.17. Boehringer Ingelheim International GmbH
• 19.18. Candel Therapeutics, Inc.
• 19.19. Cullinan Therapeutics, Inc.
• 19.20. Dr. Reddy's Laboratories Ltd.
• 19.21. Fresenius Kabi AG
• 19.22. Innovent Biologics (Suzhou) Co., Ltd.
• 19.23. Jazz Pharmaceuticals, Inc.
• 19.24. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• 19.25. MAIA Biotechnology, Inc.
• 19.26. Nuvalent, Inc.
• 19.27. OS Therapies Inc.
• 19.28. Sanofi S.A
• 19.29. Shanghai Henlius Biotech, Inc.
• 19.30. Summit Therapeutics Inc.
• 19.31. Teva Pharmaceutical Industries Ltd.
• 19.32. Viatris Inc.